Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF).
Yasser Ged(Memorial Sloan Kettering Cancer Center), Chung‐Han Lee(Memorial Sloan Kettering Cancer Center), Ritesh R. Kotecha(Memorial Sloan Kettering Cancer Center), Brian I. Rini(Vanderbilt University Medical Center), Natalie Shapnik(Memorial Sloan Kettering Cancer Center), Cihan Düzgöl(Memorial Sloan Kettering Cancer Center), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Sujata Patil(Kettering University), Oğuz Akın(Memorial Sloan Kettering Cancer Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Darren R. Feldman(Memorial Sloan Kettering Cancer Center), Ruby Gupta(Cleveland Clinic), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center)
Cited by 5
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
|Journal of Clinical Oncology|2008|907
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
|Cancer Cell|2016|855